Log in

NASDAQ:EIGR - Eiger Biopharmaceuticals Stock Price, Forecast & News

$6.80
+0.06 (+0.89 %)
(As of 04/1/2020 04:59 AM ET)
Today's Range
$6.54
Now: $6.80
$7.08
50-Day Range
$4.91
MA: $8.77
$11.99
52-Week Range
$4.55
Now: $6.80
$15.82
Volume304,000 shs
Average Volume361,121 shs
Market Capitalization$167.00 million
P/E RatioN/A
Dividend YieldN/A
Beta1.3
Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates also include Lambda, which targets type III IFN receptors; Lonafarnib for the treatment of progeria and progeroid laminopathies; Avexitide for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.
Read More
Eiger Biopharmaceuticals logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EIGR
CUSIPN/A
Phone650-272-6138

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.31 per share

Profitability

Net Income$-70,250,000.00

Miscellaneous

Employees18
Market Cap$167.00 million
Next Earnings Date5/14/2020 (Estimated)
OptionableNot Optionable

Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.


Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

How has Eiger Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Eiger Biopharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EIGR shares have decreased by 0.1% and is now trading at $6.80. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Eiger Biopharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eiger Biopharmaceuticals.

When is Eiger Biopharmaceuticals' next earnings date?

Eiger Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Eiger Biopharmaceuticals.

How were Eiger Biopharmaceuticals' earnings last quarter?

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) posted its earnings results on Friday, March, 13th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.30. View Eiger Biopharmaceuticals' earnings history.

What price target have analysts set for EIGR?

5 brokerages have issued twelve-month price objectives for Eiger Biopharmaceuticals' stock. Their forecasts range from $10.72 to $35.00. On average, they expect Eiger Biopharmaceuticals' share price to reach $24.68 in the next year. This suggests a possible upside of 262.9% from the stock's current price. View analysts' price targets for Eiger Biopharmaceuticals.

What are Wall Street analysts saying about Eiger Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Eiger Biopharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. " (1/27/2020)
  • 2. LADENBURG THALM/SH SH analysts commented, "We believe its cash is sufficient to fund operations through profitability in 2022, assuming it nets ~$50M for its after splitting it with the Progeria Research Foundation. While the last four months the news flow from Eiger’s HDV and progeria programs has been quiet, the next four months include several catalysts in these programs." (8/12/2019)

Has Eiger Biopharmaceuticals been receiving favorable news coverage?

Media stories about EIGR stock have been trending very negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eiger Biopharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View the latest news aboutEiger Biopharmaceuticals.

Are investors shorting Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 961,600 shares, an increase of 14.5% from the February 27th total of 840,100 shares. Based on an average trading volume of 399,000 shares, the days-to-cover ratio is presently 2.4 days. Approximately 4.5% of the company's shares are short sold. View Eiger Biopharmaceuticals' Current Options Chain.

Who are some of Eiger Biopharmaceuticals' key competitors?

What other stocks do shareholders of Eiger Biopharmaceuticals own?

Who are Eiger Biopharmaceuticals' key executives?

Eiger Biopharmaceuticals' management team includes the following people:
  • Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 55)
  • Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Director (Age 56)
  • Dr. David Apelian, COO, Exec. Medical Officer & Director (Age 54)
  • Mr. James P. Shaffer, Chief Bus. Officer (Age 52)
  • Mr. Sriram Ryali M.B.A., Chief Financial Officer (Age 38)

What is Eiger Biopharmaceuticals' stock symbol?

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

How do I buy shares of Eiger Biopharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eiger Biopharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $6.80.

How big of a company is Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals has a market capitalization of $167.00 million. The biotechnology company earns $-70,250,000.00 in net income (profit) each year or ($3.08) on an earnings per share basis. Eiger Biopharmaceuticals employs 18 workers across the globe. View additional information about Eiger Biopharmaceuticals.

What is Eiger Biopharmaceuticals' official website?

The official website for Eiger Biopharmaceuticals is http://www.eigerbio.com/.

How can I contact Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at ic[email protected]


MarketBeat Community Rating for Eiger Biopharmaceuticals (NASDAQ EIGR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  398 (Vote Outperform)
Underperform Votes:  275 (Vote Underperform)
Total Votes:  673
MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EIGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Featured Article: Preferred Stock

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel